Exit Strategy, Virtually
This article was originally published in Start Up
Executive Summary
The idea behind a virtual company is to put relatively little money to work in a new enterprise, get a program to a go/no go decision point, and then sell it for a big mark-up (if the data looks good) to a more completely infrastructured company. Hillman Ventures has been the main proponent of this strategy but their first "liquidation event" shows that the jury is still out on the strategy's success.
You may also be interested in...
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
A Learning Lab For Outcomes-Based Risk-Sharing Agreements
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.